Treanda

Product manufactured by Cephalon, Inc.

Application Nr Approved Date Route Status External Links
NDA022249 None Intravenous None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Treanda Is An Alkylating Drug Indicated For Treatment Of Patients With: Chronic Lymphocytic Leukemia (Cll). Efficacy Relative To First Line Therapies Other Than Chlorambucil Has Not Been Established. ( 1.1 ) Indolent B-Cell Non-Hodgkin Lymphoma (Nhl) That Has Progressed During Or Within Six Months Of Treatment With Rituximab Or A Rituximab-Containing Regimen. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia (Cll) Treanda ® Is Indicated For The Treatment Of Patients With Chronic Lymphocytic Leukemia. Efficacy Relative To First Line Therapies Other Than Chlorambucil Has Not Been Established. 1.2 Non-Hodgkin Lymphoma (Nhl) Treanda Is Indicated For The Treatment Of Patients With Indolent B-Cell Non-Hodgkin Lymphoma That Has Progressed During Or Within Six Months Of Treatment With Rituximab Or A Rituximab-Containing Regimen.

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Bendamustine Hydrochloride BENDAMUSTINE HYDROCHLORIDE ZINC4214955

Comments